FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia

/1 Comment/in , /by

The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

Read full article (External website)

You might also like
AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826Hywards / 123RF Stock Photo Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)
Trastuzumab Deruxtecan Receives Expedited Review in Japan for Gastric Cancer
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FDA approves venetoclax in 2nd-line for patients with CLL or SLL
Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational Durable Responses to JCAR017 Observed in High-Risk DLBCL
Expert Discusses Immunotherapy Advancements in a Rapidly Changing GU Field
Expert Discusses Immunotherapy Growth in Treatment Landscape of NSCLC
US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel US FDA approved CAR-T cell and BiTE immunotherapy - Updated 2-May-2018
Immunotherapy Arrives in Gastric Cancer
1 reply

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply